InvestorRoom | Kitov Pharmaceuticals http://kitovpharma.investorroom.com/ Kitov Pharmaceuticals Provides Corporate Update and Reports First Half 2017 Financial Results http://kitovpharma.investorroom.com/2017-08-16-Kitov-Pharmaceuticals-Provides-Corporate-Update-and-Reports-First-Half-2017-Financial-Results Wed, 16 Aug 2017 16:35:00 -0400 http://kitovpharma.investorroom.com/2017-08-16-Kitov-Pharmaceuticals-Provides-Corporate-Update-and-Reports-First-Half-2017-Financial-Results Kitov Submits New Drug Application to FDA for KIT-302 http://kitovpharma.investorroom.com/news-releases?item=53 Mon, 31 Jul 2017 15:29:00 -0400 http://kitovpharma.investorroom.com/news-releases?item=53 Kitov Announces Results of Study Demonstrating NT-219 Enhanced Efficacy of Keytruda® in Immune-Oncology Preclinical Model http://kitovpharma.investorroom.com/2017-07-18-Kitov-Announces-Results-of-Study-Demonstrating-NT-219-Enhanced-Efficacy-of-Keytruda-R-in-Immune-Oncology-Preclinical-Model Tue, 18 Jul 2017 08:36:00 -0400 http://kitovpharma.investorroom.com/2017-07-18-Kitov-Announces-Results-of-Study-Demonstrating-NT-219-Enhanced-Efficacy-of-Keytruda-R-in-Immune-Oncology-Preclinical-Model Kitov Pharmaceuticals Announces Pricing of $3.5 Million Registered Direct Offering http://kitovpharma.investorroom.com/news-releases?item=51 Tue, 11 Jul 2017 09:30:00 -0400 http://kitovpharma.investorroom.com/news-releases?item=51 Kitov Updates on KIT-302 New Drug Application http://kitovpharma.investorroom.com/news-releases?item=50 Anticipated PDUFA Date with FDA for Approval of Marketing on Schedule Mon, 26 Jun 2017 14:40:00 -0400 http://kitovpharma.investorroom.com/news-releases?item=50